The Aurum Institute’s Post

As we mark #WorldTBDay, it is vital to reflect on the ongoing battle against this disease. The Foundation's Head of Research, Claudia Martínez, underscores the urgency of addressing TB's impact, particularly in resource-limited settings. From barriers in accessing medications to the rise of drug-resistant strains, the challenges are immense. #Pharma companies have a critical role to play in driving progress towards ending #TB. Through collaborative efforts and by prioritising #EquitableAccess to treatment, they can ensure that no one is left behind. Watch the video ➡ https://lnkd.in/eFgGJ_up #WorldTuberculosisDay #EndTB #tuberculosis #AccesstoMedicine #EquitableAccess #AccesstoHealthcare #GlobalHealth

In honor of World AIDS Awareness Day, consider registering for this upcoming panel discussion. https://bit.ly/DSTCLTWAD

Discover the impact of endobronchial valve therapy on severe COPD/emphysema patients. Listen to key insights from Dr. Petrovic and Prof. Arschang Valipour, Director, Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie, on patient selection and procedural benefits of the Zephyr Valves. Learn more about how Zephyr Valves work: https://bit.ly/4g4aitO

Cumulatively, rare diseases are not so rare at all. There are approximately 300 million people living with rare diseases to date and 7,000 diagnosable rare conditions worldwide*.  Yet, there's still a significant gap when it comes to medical research for rare diseases. Why? Funding and investment are the primary reasons behind this gap, argues our CEO, Simon Estcourt. In this article for RARE Revolution Magazine, he discusses the current considerations for conducting clinical trials for rare diseases, approaches for overcoming challenges and how he thinks the rare disease landscape will evolve in the coming years… *The Lancet #RareDiseases #CRO #ClinicalResearch #MedicalResearch #ClinicalTrials https://lnkd.in/eq_TQtwA

⭐️ Today is #RareDiseaseDay! ⭐️ To explain why this is important and how European Reference Networks (like ERN eUROGEN) can help, I wrote a blog: https://lnkd.in/eard2X-q

Please join an insightful interview with Prof. Karolina Skonieczna-Żydecka from Pomeranian Medical University in Szczecin. Karolina discusses the proof-of-concept IMMEDIATE EU Project study, where together with Sanprobi Team, she investigates how factors like diet, inactivity, and work-related stress contribute to chronic inflammation and disease. Discover how machine learning and AI are being used to develop personalized health prediction strategies and mobile apps aimed at empowering individuals to manage their health proactively. I am really happy to take part and witness these groundbreaking advancements in the fight against non-communicable diseases. https://lnkd.in/dCaAiNPS

🔬 New Episode Alert: Ask the Expert with Peter Linsley, PhD 🔬 Dive into the complexities of Type 1 Diabetes with insights from Peter Linsley, PhD, from the Benaroya Research Institute. In this episode, Dr. Linsley breaks down the role of alpha-centric TCRs in T1D, offering valuable perspectives on the immune system's involvement in disease progression. 📽️ Watch now to explore Dr. Linsley's expertise and expand your understanding of T1D research! https://lnkd.in/geGfeWax #Type1Diabetes #AlphaCentricTCRs #TheSugarScience #DiabetesResearch

https://lnkd.in/gRvvD5X6 Join us in this campaign. Spreading awareness on how to stop the spread of HIV AIDS. If you take pep before 3 days after exposure, you don't contract the disease. *PEP* stands for post-exposure prophylaxis. The word “prophylaxis” means to prevent or control the spread of an infection or disease. PEP means taking HIV medicines within 72 hours (3 days) after a possible exposure to HIV to prevent HIV. PEP should be used only in emergency situations.

Why #WHO's 2025 #Riverblindness Eradication Goal In Africa May Not Be Feasible. In this discussion with Prof. #Stephen Ghogomu, head of the #Molecular and cell biology laboratory at the University of Buea, we delved into his extensive research efforts aimed at eradicating #onchocerciasis, commonly known as Riverblindness. In part 1 of this episode, Prof. Ghogomu discusses why the World Health Organization 's goal to eradicate Riverblindness by 2025 is not feasible. He highlights the numerous challenges and limitations in the fight against this debilitating disease in Africa, including logistical hurdles, the complexity of the disease's transmission, research funding and the socio-economic factors at play. Prof. Ghogomu also shares his expert perspective on the necessary steps and innovative strategies needed to move forward in the battle against Riverblindness. Tune in to gain valuable insights from a leading expert in the field. Follow part 2 of this interview on his effort in #Vaccine and #diagnostic development against Riverblindness. FOLEFAC Charlemagne ASONGANYI Jude Tsafack Zefack Robert Adamu Shey University of Buea Funeh Cyprine N. Lum Abienwi #onchocerciasis #riverblindness #research https://lnkd.in/eaVJ4fUn

In this Research and Science Diaries (RSD) podcast, Prof. Stephen #Ghogomu highlights why the WHO’s 2025 Riverblindness eradication goal may not be feasible, emphasizing significant disparities in Cameroon and other minority communities. Socio-economic and logistical challenges, like access to remote areas and sustained treatment, are significant barriers. The complexity of disease transmission and the need for research funding underscore broader health inequities. This timely discussion provides valuable insights and strategies. Integrating medical innovation and socio-economic considerations is essential to combat this disease. #SocialEpidemiologyLab #HealthEquity #RiverblindnessEradication #WHO